The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease.

Susrichit PhrueksotsaiKanokwan PinyopornpanishJuntima EuathrongchitApinya LeerapunArintaya PhrommintikulSupawan BuranapinSiriporn C ChattipakornSatawat Thongsawat

Published in: Journal of gastroenterology and hepatology (2021)

Dapagliflozin treatment for 12 weeks is associated with improvement in hepatic fat content, a decrease in visceral fat and bodyweight, enhanced glycemic control, and improved liver biochemistry among T2DM patients with NAFLD.

Keyphrases

glycemic control
type diabetes
insulin resistance
adipose tissue
blood glucose
fatty acid
weight loss
metabolic syndrome
gestational age
liver fibrosis